Nowe leki ewolucją leczenia hemofilii A
Słowa kluczowe:
hemofilia A, emicizumab, efanesoktokog alfa, FVIIIStreszczenie
Hemofilia A to choroba genetyczna związana z chromosomem płci, wywołana przez niedobory czynnika VIII. Celem jej leczenia jest zapobieganie krwawieniom oraz minimalizacja ryzyka powikłań spowodowanych przez niewystarczające krzepnięcie krwi. Obecnie wiadomo, że dawka i częstotliwość terapii zastępczych czynnikiem VIII wymaganych do ograniczenia krwawień różnią się u poszczególnych osób i mogą zmieniać się w przypadku tej samej osoby z biegiem czasu, co oznacza, że standaryzowana dawka i schemat leczenia mogą nie zapewniać optymalnego leczenia u wszystkich pacjentów. W tej pracy przyjrzymy się metodą leczenie tej choroby które są z nami obecne od pewnego czasu jak leczenie przez: administrowanie czynnika VIII, koncentratami rekombinowanymi FVIII czy stosowanie czynników omijających przez nieczynnikową terapię zastępczą aż po terapię genową. Zestawimy również ze sobą najbardziej obiecujące na ten moment leki efanesoktokog alfa oraz emicizumab.
Bibliografia
Abdelgawad HAH, Foster R, Otto M. Nothing short of a revolution: Novel extended half-life factor VIII replacement products and non-replacement agents reshape the treatment landscape in hemophilia A. Blood Rev. 2024;64:101164. doi:10.1016/j.blre.2023.101164
Reid E, Segaloff A. Distribution of growth hormone among cell fractions isolated from pituitary gland. Proc Soc Exp Biol Med Soc Exp Biol Med N Y N. 1958;97(1):187-188. doi:10.3181/00379727-97-23683
Keam SJ. Efanesoctocog Alfa: First Approval. Drugs. 2023;83(7):633-638. doi:10.1007/s40265-023-01866-9
Srivastava A, Santagostino E, Dougall A, et al. WFH Guidelines for the Management of Hemophilia, 3rd edition. Haemophilia. 2020;26(S6):1-158. doi:10.1111/hae.14046
Cho S, Perry AM, Cheng AM, Wang C, Rico JF. Advances in Hemophilia A Management. Adv Pediatr. 2022;69(1):133-147. doi:10.1016/j.yapd.2022.03.009
Mahlangu J, Powell JS, Ragni MV, et al. Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A. Blood. 2014;123(3):317-325. doi:10.1182/blood-2013-10-529974
Powell JS, Josephson NC, Quon D, et al. Safety and prolonged activity of recombinant factor VIII Fc fusion protein in hemophilia A patients. Blood. 2012;119(13):3031-3037. doi:10.1182/blood-2011-09-382846
Tiede A, Brand B, Fischer R, et al. Enhancing the pharmacokinetic properties of recombinant factor VIII: first-in-human trial of glycoPEGylated recombinant factor VIII in patients with hemophilia A. J Thromb Haemost. 2013;11(4):670-678. doi:10.1111/jth.12161
Lissitchkov T, Willemze A, Katragadda S, Rice K, Poloskey S, Benson C. Efanesoctocog alfa for hemophilia A: results from a phase 1 repeat-dose study. Blood Adv. 2022;6(4):1089-1094. doi:10.1182/bloodadvances.2021006119
Von Drygalski A, Chowdary P, Kulkarni R, et al. Efanesoctocog Alfa Prophylaxis for Patients with Severe Hemophilia A. N Engl J Med. 2023;388(4):310-318. doi:10.1056/NEJMoa2209226
Plug I, Van Der Bom JG, Peters M, et al. Mortality and causes of death in patients with hemophilia, 1992–2001: a prospective cohort study. J Thromb Haemost. 2006;4(3):510-516. doi:10.1111/j.1538-7836.2006.01808.x
Dodd RY. Emerging pathogens and their implications for the blood supply and transfusion transmitted infections. Br J Haematol. 2012;159(2):135-142. doi:10.1111/bjh.12031
Windyga J, Chojnowski K, Klukowska A, et al. Część I: Wytyczne postępowania w hemofilii A i B niepowikłanej inhibitorem czynnika VIII i IX (wydanie zaktualizowane). Acta Haematol Pol. 2016;47(2):86-114. doi:10.1016/j.achaem.2016.04.009
Peyvandi F, Garagiola I. Product type and other environmental risk factors for inhibitor development in severe hemophilia A. Res Pract Thromb Haemost. 2018;2(2):220-227. doi:10.1002/rth2.12094
Key NS, Negrier C. Coagulation factor concentrates: past, present, and future. The Lancet. 2007;370(9585):439-448. doi:10.1016/S0140-6736(07)61199-4
Pipe S. Recombinant clotting factors. Thromb Haemost. 2008;99(11):840-850. doi:10.1160/TH07-10-0593
Shima M, Yoshioka A. Products Used to Treat Hemophilia: Recombinant Products. In: Lee CA, Berntorp EE, Hoots WK, eds. Textbook of Hemophilia. 1st ed. Wiley; 2014:163-173. doi:10.1002/9781118398258.ch23
Oldenburg J. Optimal treatment strategies for hemophilia: achievements and limitations of current prophylactic regimens. Blood. 2015;125(13):2038-2044. doi:10.1182/blood-2015-01-528414
Warren BB, Thornhill D, Stein J, et al. Young adult outcomes of childhood prophylaxis for severe hemophilia A: results of the Joint Outcome Continuation Study. Blood Adv. 2020;4(11):2451-2459. doi:10.1182/bloodadvances.2019001311
Gouw SC, Van Der Bom JG, Ljung R, et al. Factor VIII Products and Inhibitor Development in Severe Hemophilia A. N Engl J Med. 2013;368(3):231-239. doi:10.1056/NEJMoa1208024
Peyvandi F, Mannucci PM, Garagiola I, et al. A Randomized Trial of Factor VIII and Neutralizing Antibodies in Hemophilia A. N Engl J Med. 2016;374(21):2054-2064. doi:10.1056/NEJMoa1516437
Négrier C, Gomperts ED, Oldenburg J. The history of FEIBA: a lifetime of success in the treatment of haemophilia complicated by an inhibitor. Haemophilia. 2006;12(s5):4-13. doi:10.1111/j.1365-2516.2006.01379.x
Qadura M, Waters B, Burnett E, et al. Recombinant and plasma-derived factor VIII products induce distinct splenic cytokine microenvironments in hemophilia A mice. Blood. 2009;114(4):871-880. doi:10.1182/blood-2008-09-174649
Hartholt RB, Van Velzen AS, Peyron I, Ten Brinke A, Fijnvandraat K, Voorberg J. To serve and protect: The modulatory role of von Willebrand factor on factor VIII immunogenicity. Blood Rev. 2017;31(5):339-347. doi:10.1016/j.blre.2017.07.001
Powell JS. Lasting power of new clotting proteins. Hematology. 2014;2014(1):355-363. doi:10.1182/asheducation-2014.1.355
Klukowska A, Zawilska K. Koncentraty czynników krzepnięcia o przedłużonym działaniu w leczeniu hemofilii. Acta Haematol Pol. 2015;46(4):299-303. doi:10.1016/j.achaem.2015.04.006
Wynn T, Gumuscu B. Potential role of a new PEGylated recombinant factor VIII for hemophilia A. J Blood Med. Published online June 2016:121. doi:10.2147/JBM.S82457
Jazayeri JA, Carroll GJ. Half‐Life Extension by Fusion to the Fc Region. In: Kontermann R, ed. Therapeutic Proteins. 1st ed. Wiley; 2012:157-188. doi:10.1002/9783527644827.ch9
Pipe SW, Montgomery RR, Pratt KP, Lenting PJ, Lillicrap D. Life in the shadow of a dominant partner: the FVIII-VWF association and its clinical implications for hemophilia A. Blood. 2016;128(16):2007-2016. doi:10.1182/blood-2016-04-713289
Anand R, Vallooran J. Polypeptides. In: Engineering of Biomaterials for Drug Delivery Systems. Elsevier; 2018:299-315. doi:10.1016/B978-0-08-101750-0.00011-8
Konkle BA, Shapiro AD, Quon DV, et al. BIVV001 Fusion Protein as Factor VIII Replacement Therapy for Hemophilia A. N Engl J Med. 2020;383(11):1018-1027. doi:10.1056/NEJMoa2002699
Howard M, McKinley D, Sanabria F, Ko RH, Nissen F. Evaluation of the Safety of Emicizumab Prophylaxis in Persons with Hemophilia A: An Updated Summary of Thrombotic Events and Thrombotic Microangiopathies. Blood. 2021;138(Supplement 1):3186-3186. doi:10.1182/blood-2021-146147
Peyvandi F, Garagiola I, Abbattista M. Fitusiran in haemophilia: a breakthrough drug with many unknowns. The Lancet. 2023;401(10386):1400-1401. doi:10.1016/S0140-6736(23)00514-7
Earnshaw SR, Graham CN, McDade CL, Spears JB, Kessler CM. Factor VIII alloantibody inhibitors: cost analysis of immune tolerance induction vs. prophylaxis and on‐demand with bypass treatment. Haemophilia. 2015;21(3):310-319. doi:10.1111/hae.12621
Teitel JM. Treatment and prevention of bleeding in congenital hemophilia A patients with inhibitors. Transfus Apher Sci. 2018;57(4):466-471. doi:10.1016/j.transci.2018.07.011
Baglin T, Koch A, Mocanu I, Makhaldiani L, Huntington JA. Serpinpc in Persons with Severe Hemophilia (PwH): Updated Results from a Multi-Center, Multi-Part, First-in-Human Study. Blood. 2022;140(Supplement 1):460-461. doi:10.1182/blood-2022-159631
Young G, Srivastava A, Kavakli K, et al. Efficacy and Safety of Fitusiran Prophylaxis, an siRNA Therapeutic, in a Multicenter Phase 3 Study (ATLAS-INH) in People with Hemophilia A or B, with Inhibitors (PwHI). Blood. 2021;138(Supplement 1):4-4. doi:10.1182/blood-2021-150273
Waters EK, Sigh J, Friedrich U, Hilden I, Sørensen BB. Concizumab, an anti‐tissue factor pathway inhibitor antibody, induces increased thrombin generation in plasma from haemophilia patients and healthy subjects measured by the thrombin generation assay. Haemophilia. 2017;23(5):769-776. doi:10.1111/hae.13260
Mahlangu JN. Progress in the Development of Anti-tissue Factor Pathway Inhibitors for Haemophilia Management. Front Med. 2021;8:670526. doi:10.3389/fmed.2021.670526
Lenting PJ, Denis CV, Christophe OD. Emicizumab, a bispecific antibody recognizing coagulation factors IX and X: how does it actually compare to factor VIII? Blood. 2017;130(23):2463-2468. doi:10.1182/blood-2017-08-801662
Sampei Z, Igawa T, Soeda T, et al. Identification and Multidimensional Optimization of an Asymmetric Bispecific IgG Antibody Mimicking the Function of Factor VIII Cofactor Activity. Lenting PJ, ed. PLoS ONE. 2013;8(2):e57479. doi:10.1371/journal.pone.0057479
Retout S, Schmitt C, Petry C, Mercier F, Frey N. Population Pharmacokinetic Analysis and Exploratory Exposure–Bleeding Rate Relationship of Emicizumab in Adult and Pediatric Persons with Hemophilia A. Clin Pharmacokinet. 2020;59(12):1611-1625. doi:10.1007/s40262-020-00904-z
Ragni MV. The effect of emicizumab regimen on haemophilia outcomes. Lancet Haematol. 2019;6(6):e286-e287. doi:10.1016/S2352-3026(19)30070-5
Oldenburg J, Mahlangu JN, Kim B, et al. Emicizumab Prophylaxis in Hemophilia A with Inhibitors. N Engl J Med. 2017;377(9):809-818. doi:10.1056/NEJMoa1703068
Shima M, Hanabusa H, Taki M, et al. Factor VIII–Mimetic Function of Humanized Bispecific Antibody in Hemophilia A. N Engl J Med. 2016;374(21):2044-2053. doi:10.1056/NEJMoa1511769
Berntorp E, Hermans C, Solms A, Poulsen L, Mancuso ME. Optimising prophylaxis in haemophilia A: The ups and downs of treatment. Blood Rev. 2021;50:100852. doi:10.1016/j.blre.2021.100852
Kizilocak H, Marquez‐Casas E, Malvar J, Carmona R, Young G. Determining the approximate factor VIII level of patients with severe haemophilia A on emicizumab using in vivo global haemostasis assays. Haemophilia. 2021;27(5):730-735. doi:10.1111/hae.14359
Chopra SS. Industry Funding of Clinical Trials: Benefit or Bias? JAMA. 2003;290(1):113. doi:10.1001/jama.290.1.113
Ozelo MC, Mahlangu J, Pasi KJ, et al. Valoctocogene Roxaparvovec Gene Therapy for Hemophilia A. N Engl J Med. 2022;386(11):1013-1025. doi:10.1056/NEJMoa2113708
Mahlangu J, Kaczmarek R, Von Drygalski A, et al. Two-Year Outcomes of Valoctocogene Roxaparvovec Therapy for Hemophilia A. N Engl J Med. 2023;388(8):694-705. doi:10.1056/NEJMoa2211075
Nathwani AC, Tuddenham E, Chowdary P, et al. GO-8: Preliminary Results of a Phase I/II Dose Escalation Trial of Gene Therapy for Haemophilia a Using a Novel Human Factor VIII Variant. Blood. 2018;132(Supplement 1):489-489. doi:10.1182/blood-2018-99-118256
Pasi KJ, Rangarajan S, Mitchell N, et al. Multiyear Follow-up of AAV5-hFVIII-SQ Gene Therapy for Hemophilia A. N Engl J Med. 2020;382(1):29-40. doi:10.1056/NEJMoa1908490
Pipe SW, Ferrante F, Reis M, et al. First-in-Human Gene Therapy Study of AAVhu37 Capsid Vector Technology in Severe Hemophilia A - BAY 2599023 has Broad Patient Eligibility and Stable and Sustained Long-Term Expression of FVIII. Blood. 2020;136(Supplement 1):44-45. doi:10.1182/blood-2020-139803
Ohmori T, Mizukami H, Ozawa K, Sakata Y, Nishimura S. New approaches to gene and cell therapy for hemophilia. J Thromb Haemost. 2015;13:S133-S142. doi:10.1111/jth.12926
Bullement A, Knowles ES, DasMahapatra P, Ali T, Preblick R. Cost-Effectiveness Analysis of rFVIIIFc Versus Contemporary rFVIII Treatments for Patients with Severe Hemophilia A Without Inhibitors in the United States. PharmacoEconomics - Open. 2021;5(4):625-633. doi:10.1007/s41669-021-00283-6
Samelson‐Jones BJ, Guelcher C, Kuhn J, et al. Real‐world cost estimates of initiating emicizumab in US patients with haemophilia A. Haemophilia. 2021;27(4):591-598. doi:10.1111/hae.14347
Moorehead PC, Chan AKC, Lemyre B, et al. A Practical Guide to the Management of the Fetus and Newborn With Hemophilia. Clin Appl Thromb. 2018;24(9_suppl):29S-41S. doi:10.1177/1076029618807583
Mbanya DN, Diop S, Ndoumba Mintya AN, El Kiaby M. Hemophilia care in Africa: Status and challenges. Transfus Clin Biol. 2021;28(2):158-162. doi:10.1016/j.tracli.2021.01.008
Pierce GF, Adediran M, Diop S, et al. Achieving access to haemophilia care in low-income and lower-middle-income countries: expanded Humanitarian Aid Program of the World Federation of Hemophilia after 5 years. Lancet Haematol. 2022;9(9):e689-e697. doi:10.1016/S2352-3026(22)00209-5
Lambert C, Meité N, Kouassi GK, et al. Nonreplacement therapy for hemophilia in low-income countries: experience from a prospective study in Ivory Coast. Res Pract Thromb Haemost. 2023;7(1):100033. doi:10.1016/j.rpth.2022.100033
Opublikowane
7 lipca 2024
Prawa autorskie (c) 2024 Łukasz Grajcarek; Tola Kotkiewicz, Marcin Jezierzański, Julia Gawron, Tomasz Furgoł, Witold Kimla
Licencja
Utwór dostępny jest na licencji Creative Commons Uznanie autorstwa – Użycie niekomercyjne – Bez utworów zależnych 4.0 Międzynarodowe.
